Key Takeaways & Executive Findings
- •• MSCs exhibit regenerative and immunomodulatory properties that can rejuvenate aged immune cells and restore immune homeostasis, offering a promising strategy to counteract immunosenescence. • The review systematically summarizes recent discoveries on MSC-based interventions, highlighting their ability to mitigate excessive inflammation and foster tissue repair in the context of aging. • Key challenges include variations in MSC sources, donor variability, and lack of standardized protocols, which must be addressed to enhance therapeutic precision. • Critical unresolved issues such as long-term safety, efficacy, and context-specific mechanisms need further investigation to translate MSC therapies into clinical practice for aging-related immune decline.
Abstract
Aging leads to a gradual decline in immune function, termed immunosenescence, which significantly elevates the susceptibility to infections, cancers, and other aging-related diseases. Recent advancements have shed light on the molecular underpinnings of immune aging and pioneered novel therapeutic interventions to counteract its effects. Mesenchymal stem cells (MSCs)-a type of multipotent stromal cells with regenerative potential, low immunogenicity, and strong immunomodulatory properties-are increasingly recognized as a promising therapeutic option to reverse or alleviate immunosenescence-related dysfunction. This review systematically summarizes recent discoveries on how MSCs counteract immune aging, particularly their ability to rejuvenate aged immune cells and restore immune homeostasis. It also addresses key challenges, such as variations in MSC sources, donor variability, and the lack of standardized protocols, while proposing future directions to enhance therapeutic precision. Although preclinical and clinical studies highlight the potential of MSC-based strategies for delaying immunosenescence, critical issues remain unresolved, including long-term safety and efficacy, optimizing cell delivery systems, and elucidating context-specific mechanisms. Addressing these challenges will accelerate the development of MSC-based therapies to combat aging-associated immune decline.
1. Introduction
Aging is a natural yet complex biological process that remains incompletely understood. A central challenge in aging is immunosenescence-the gradual decline of immune function with age [1, 2]. This decline compromises the body's ability to fight infections, respond to vaccines, and maintain immune balance, which significantly heightens the vulnerability of the elderly to infections and chronic inflammatory diseases, such as rheumatoid arthritis, cancer, atherosclerosis, type 2 diabetes, and neurodegenerative diseases [3]. Recent breakthroughs have begun to unravel the molecular mechanisms driving aging, leading to innovative therapeutic approaches to delay or even reverse aging [4]. For example, senescent cell scavengers, dasatinib and quercetin, can selectively eliminate aged, dysfunctional cells, and have shown promise in delaying age-related conditions in preclinical studies [5, 6].
Among emerging therapies, mesenchymal stem cells (MSCs) stand out for their unique regenerative and immunomodulatory properties. MSCs can self-renew, differentiate into diverse cell types, and suppress harmful immune responses, making them a compelling candidate for rejuvenating the aging immune system [7]. This review explores the connections between aging, immunosenescence, and MSC-based therapies. We explain how aging disrupts the immune system's ability to fight threats while avoiding overreaction. We then elucidate the multifaceted roles that MSCs play in modulating immune responses—from mitigating excessive inflammation to fostering tissue repair and regeneration. Finally, we discuss the potential of MSC-based therapies to improve health span in aging populations and outline critical challenges that must be addressed to translate these findings into real-world treatments.
Loading authentic research manuscript (Pages 1–5)...
Xu Wang, Dan Guo, Chengmei He, Xiaoxi Wang, Yi Wei, Fengchun Zhang, Li Wang, Yanlei Yang (2026). Clinical application of mesenchymal stem cells in immunosenescence: a qualitative review of their potential and challenges. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-025-04360-z
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is immunosenescence?
Immunosenescence refers to the gradual decline of immune function with age, leading to increased susceptibility to infections, cancers, and other aging-related diseases.
How can mesenchymal stem cells (MSCs) counteract immunosenescence?
MSCs possess regenerative and immunomodulatory properties that can rejuvenate aged immune cells, restore immune homeostasis, and mitigate excessive inflammation, thereby potentially alleviating immunosenescence-related dysfunction.
What are the main challenges in MSC-based therapies for immunosenescence?
Key challenges include variations in MSC sources, donor variability, lack of standardized protocols, and unresolved issues regarding long-term safety, efficacy, and context-specific mechanisms.
What is the significance of this review?
This review systematically summarizes recent discoveries on MSC-based strategies for delaying immunosenescence, identifies critical challenges, and proposes future directions to enhance therapeutic precision, thereby accelerating the development of MSC-based therapies for aging-associated immune decline.
What are the future directions for MSC-based therapies in aging?
Future research should focus on optimizing cell delivery systems, elucidating context-specific mechanisms, and conducting long-term safety and efficacy studies to translate MSC therapies into clinical practice.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.